Key result
Tomato extract and lycopene reduce doxorubicin-induced CPKMB elevation by ~69% and ameliorate cardiac injury.
Why the study?
The protective effects of tomato extract and lycopene against acute doxorubicin-induced myocardial toxicity were not well established.
Does tomato extract or lycopene prevent doxorubicin-induced cardiotoxicity in mice?
Does tomato extract or lycopene prevent doxorubicin-induced cardiotoxicity in mice?
Absolute Event Rate: 468.5% vs 1502.6%
p-value: p=<0.05
Tomato extract and lycopene demonstrate cardioprotective effects against acute doxorubicin-induced cardiotoxicity in a mouse model.
Should not change practice; hypothesis-generating for lycopene cardioprotection in doxorubicin-treated patients.
The protective effect of tomato extract and lycopene on acute doxorubicin-induced myocardial toxicity was evaluated in mice. Doxorubicin toxicity, induced by asingle intraperitoneal injection (15 mg/kg), was revealed by elevated serum CPKMB and histopathological observations. Tomato extract (1.2 and 2.4 g/kg, i.p.) andlycopene (1.7 and 3.5 mg/kg, i.p.), prevented the rise in serum CPKMB and ameliorated cardiac cell injury. These results suggest that tomato extract andlycopene inhibit doxorubicin-induced cardiotoxicity and might serve as a combination chemotherapeutic agent with doxorubicin to limit its cardiotoxic effects.
No takes yet. Share an insight, caveat, or question.
Karimi et al. (2005) studied Doxorubicin-induced cardiotoxicity (n=36). Tomato extract and lycopene vs. Doxorubicin alone was evaluated on Serum CPKMB levels (IU/L) (p=<0.05). Tomato extract (2.4 g/kg) and lycopene (3.5 mg/kg) significantly reduced doxorubicin-induced serum CPKMB elevation (492.4 and 468.5 IU/L, respectively, vs 1502.6 IU/L) and ameliorated cardiac injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: